PolyPid Announces Eligibility for European Medicines Agency Centralized Procedure for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Surgery

Centralized Procedure Allows for Submission of a Single Marketing Application to the European Medicines Agency that, if Approved, Would Allow D-PLEX 100 to be Marketed in All EU Member States D-PLEX 100 is Eligible for Centralized Procedure Under the Therapeutic Innovation Criteria PETACH